Cargando…

Effect of RIF1 on response of non-small-cell lung cancer patients to platinum-based chemotherapy by regulating MYC signaling pathway

Platinum-based chemotherapy is used as first-line therapy for advanced non-small-cell lung cancer (NSCLC). However, there is no effective indicator to predict whether the patient would be chemo-resistant or sensitive to the therapy. In addition, it is urgent to elucidate the mechanisms of cisplatin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mei, Ying, Liu, Yong-Bin, Hu, Dong-Li, Zhou, Hong-Hao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6231216/ https://www.ncbi.nlm.nih.gov/pubmed/30443189 http://dx.doi.org/10.7150/ijbs.27710

Ejemplares similares

Meta-Analysis on Pharmacogenetics of Platinum-Based Chemotherapy in Non Small Cell Lung Cancer (NSCLC) Patients
por: Yin, Ji-Ye, et al.
Publicado: (2012)

Gene-gene and gene-environment interaction data for platinum-based chemotherapy in non-small cell lung cancer
por: Wang, Lei-Yun, et al.
Publicado: (2018)

RIF1 promotes human epithelial ovarian cancer growth and progression via activating human telomerase reverse transcriptase expression
por: Liu, Yong-Bin, et al.
Publicado: (2018)

The impact of both platinum-based chemotherapy and EGFR-TKIs on overall survival of patients with advanced non-small cell lung cancer
por: Zhang, Jian-Wei, et al.
Publicado: (2014)

Activation of the TGF-β Pathway Enhances the Efficacy of Platinum-Based Chemotherapy in Small Cell Lung Cancer Patients
por: Lin, Anqi, et al.
Publicado: (2022)

Roles of microRNAs in the resistance to platinum based chemotherapy in the non-small cell lung cancer
por: Zang, Hongjing, et al.
Publicado: (2017)

A prognostic model for platinum‐doublet as second‐line chemotherapy in advanced non‐small‐cell lung cancer patients
por: Mo, Hongnan, et al.
Publicado: (2016)

RIF1 promotes tumor growth and cancer stem cell-like traits in NSCLC by protein phosphatase 1-mediated activation of Wnt/β-catenin signaling
por: Mei, Ying, et al.
Publicado: (2018)

Silencing RIF1 decreases cell growth, migration and increases cisplatin sensitivity of human cervical cancer cells
por: Mei, Ying, et al.
Publicado: (2017)

Correction: RIF1 promotes tumor growth and cancer stem cell-like traits in NSCLC by protein phosphatase 1-mediated activation of Wnt/β-catenin signaling
por: Mei, Ying, et al.
Publicado: (2021)

Association between DNA mismatch repair gene polymorphisms and platinum-based chemotherapy toxicity in non-small cell lung cancer patients
por: Liu, Jun-Yan, et al.
Publicado: (2017)

Echocardiography and cardiac biomarkers in patients with non-small cell lung cancer treated with platinum-based chemotherapy
por: Omersa, Daniel, et al.
Publicado: (2016)

Rechallenge with First-Line Platinum Chemotherapy for Sensitive-Relapsed Small-Cell Lung Cancer
por: Shiozawa, Toshihiro, et al.
Publicado: (2018)

Gene-gene and gene-environment interactions influence platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients
por: Cui, Jia-Jia, et al.
Publicado: (2017)

Consolidation Chemotherapy with Docetaxel after Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer: A Preliminary Report
por: Attarian, Hamid, et al.
Publicado: (2011)

First-line pemetrexed-platinum doublet chemotherapy with or without bevacizumab in non-squamous non-small cell lung cancer: A real-world propensity score-matched study in China
por: Qi, Fei, et al.
Publicado: (2019)

Plasma miR-32 levels in non-small cell lung cancer patients receiving platinum-based chemotherapy can predict the effectiveness and prognosis of chemotherapy
por: Xu, Shuyuan, et al.
Publicado: (2019)

Serum APE1 as a predictive marker for platinum-based chemotherapy of non-small cell lung cancer patients
por: Zhang, Shiheng, et al.
Publicado: (2016)

Non-Coding RNA Polymorphisms (rs2910164 and rs1333049) Associated With Prognosis of Lung Cancer Under Platinum-Based Chemotherapy
por: Chen, Yi-Xin, et al.
Publicado: (2021)

Role of BCL2-associated athanogene in resistance to platinum-based chemotherapy in non-small-cell lung cancer
por: WANG, YADI, et al.
Publicado: (2016)

NANOG as an adverse predictive marker in advanced non–small cell lung cancer treated with platinum-based chemotherapy
por: Chang, Boksoon, et al.
Publicado: (2017)

Pembrolizumab plus platinum-based chemotherapy for squamous non-small cell lung cancer: the new kid on the block
por: Hockenhull, Kimberley, et al.
Publicado: (2021)

Pharmacological ascorbate improves the response to platinum-based chemotherapy in advanced stage non-small cell lung cancer
por: Furqan, Muhammad, et al.
Publicado: (2022)

Elevating CDCA3 levels in non-small cell lung cancer enhances sensitivity to platinum-based chemotherapy
por: Kildey, Katrina, et al.
Publicado: (2021)

SOCS3 protein expression predicts the responses of advanced non-small cell lung cancer patients to platinum-based chemotherapy
por: Zhang, Xiao-Ming, et al.
Publicado: (2023)

Efficacy of platinum-based adjuvant chemotherapy in T2aN0 stage IB non-small cell lung cancer
por: Park, Seong Yong, et al.
Publicado: (2013)

Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer
por: Baka, S, et al.
Publicado: (2008)

Metabolites as Prognostic Markers for Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Platinum-Doublet Chemotherapy
por: Hao, Desirée, et al.
Publicado: (2020)

Elevated serum levels of vascular endothelial growth factor predict a poor prognosis of platinum-based chemotherapy in non-small cell lung cancer
por: Zang, Jialan, et al.
Publicado: (2017)

Platinum‐combination chemotherapy with or without immune‐checkpoint inhibitor in patients with postoperative recurrent non‐small cell lung cancer previously treated with adjuvant platinum‐doublet chemotherapy: A multicenter retrospective study
por: Hisakane, Kakeru, et al.
Publicado: (2023)

Predictive Value of XPD Polymorphisms on Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Qiu, Mantang, et al.
Publicado: (2013)

Quantitative comparison of the efficacies and safety profiles of three first-line non-platinum chemotherapy regimens for advanced non-small cell lung cancer
por: Yang, Qian-Yu, et al.
Publicado: (2022)

XRCC3 Thr241Met Is Associated with Response to Platinum-Based Chemotherapy but Not Survival in Advanced Non-Small Cell Lung Cancer
por: Qiu, Mantang, et al.
Publicado: (2013)

Effect of Polymorphisms in XPD on Clinical Outcomes of Platinum-Based Chemotherapy for Chinese Non-Small Cell Lung Cancer Patients
por: Wu, Wenting, et al.
Publicado: (2012)

Incidence of chemotherapy discontinuation and characteristics of elderly patients with non-small cell lung cancer treated with platinum-based doublets
por: Alexa, Teodora, et al.
Publicado: (2014)

The Efficacy and Safety of Platinum/Vinorelbine as More Than Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer
por: Song, Ik-Chan, et al.
Publicado: (2015)

Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer
por: Shin, Junghoon, et al.
Publicado: (2019)

The power of immunotherapy plus platinum–based chemotherapy for locally advanced or early stage non-small cell lung cancer
por: Hofman, Paul
Publicado: (2020)

Identification of Proteins Deregulated by Platinum-Based Chemotherapy as Novel Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer
por: Ryan, Sarah-Louise, et al.
Publicado: (2021)

Consolidation With Pembrolizumab and Nab-Paclitaxel After Induction Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer
por: Patel, Shetal A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ipcl81qqoeggmuu2hneerfq4ql